All News
Measureable Benefits to Treat-to-Target Management in RA
Desai and colleagues have published that when a learning collaborative group focused on a treat‐to‐target approach was compared to usual care, a modest but significant impact on implementation, treatment changes and patient outcomes in RA patients managed with a treat‐to‐target approach was seen.
Read Article
Links:
Dr. John Cush RheumNow ( View Tweet)
Weekly Semaglutide for Weight Loss in Adults
NEJM has reported the results of a trial showing semaglutide once weekly plus lifestyle intervention was associated with sustained, weight loss in overweight or obese adults; such that nearly one-third lost over 20% of their body weight.
Read Article
ACR Promotes New COVID-19 Vaccine Clinical Guidance for Rheumatic Patients
The American College of Rheumatology has published a draft guidance on the use of COVID-19 vaccination in rheumatic disease and musculoskeletal disease patients, based on the efforts of the North American Task force. The document provides guidance to rheumatology providers on the use of the COVID-19 vaccine and the associated management of RMD patients around the time of vaccination. Here is a summary of the recommendations.
Read Article
Synovial Tissue Signature Guiding Targeted IL-6 Therapy in RA
RNA sequencing and classification of RA subsets has proven useful. RNA sequencing-based stratification of RA synovial tissue showed stronger associations with clinical responses compared with histopathological classification. Additionally, for patients with low or absent B-cell lineage expression signature in synovial tissue, tocilizumab is more effective than rituximab.
Read Article
Comorbidity and Drugs Drive COVID-19 Severity and Survival in Rheumatic Disease
While comorbidities are associated with severe COVID-19 infection, it appears they also influence severity and survival in rheumatic disease (RMD), according to a a French cohort study,
Read Article
Links:
Links:
RheumNow Podcast – Tofacitinib Safety Concerns (2.5.2021)
Dr. Jack Cush reviews and discusses the news and journal reports from the past week on RheumNow.com.
Read Article
Cardiac and Cancer Signals Tofacitinib Safety Alert from FDA
The FDA has notified healthcare professionals of a safety alert concerning tofacitinib (Xeljanz), noting that preliminary results from a long-term safety clinical trial show an increased risk of serious heart-related problems and cancer with tofacitinib (compared to adalimumab) when given to
Read Article
Links:
Dr. John Cush RheumNow ( View Tweet)
Health Canada Approves Subcutaneous Infliximab Biosimilar
The infliximab biosimilar CT-P13, developed by Celltrion and marketed as Remsima has been approved by HealthCanad for subcutaneous (SC) use in all the indications for infliximab.
Read Article
Vagal Nerve Stimulation in Rheumatoid Arthritis
Lancet Rheumatology has reported the results of a proof of concept trial, wherein vagal nerve stimulation was shown to ameliorate RA disease activity. The intervention involved non-invasive stimulation of the auricular branch of the vagus nerve using a wearable vagus nerve stimulation device for up to 30 min per day, delivering pulses of 20 kHz.
Read Article
RheumNow Podcast – Rheumatology Burnout (1.29.2021)
Dr. Jack Cush reviews this past week's journal articles and news features on RheumNow.com. Colchicine, vaccine rollout, risk of RA in endometriosis patients, tREACH trial, lupus nephritis news, rheumatology burnout and more.
Read Article
Calculating Serious Infection Risk in IMID Patients
Predictive modeling of data derived from the DANBIO registry (of treated IMID patients) revealed a 4 fold increased risk of serious infection (SIE) in those starting biologic DMARD (bDMARD) treatment. From this large dataset, researchers developed a simple prediction model to estimate future infection risk that may inform shared decision-making in individual patients.
Read Article
JAK Inhibitor Misses Endpoint in Safety Study. Now What?
Pfizer announced results Wednesday from its FDA-mandated postmarketing safety study of tofacitinib (Xeljanz), and they don't bode well for the drug and possibly others in its class.
Read Article
Links:
Links:
Links: